ArticleCureus2026
Long-Term Evaluation of Roux-en-Y Hepaticojejunostomy in Benign Biliary Diseases: A Retrospective Single-Center Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRoux-en-Y hepaticojejunostomy is the standard procedure for restoring biliary-enteric continuity in benign biliary diseases, including choledochal cysts, post-cholecystectomy bile duct injuries, oriental cholangiohepatitis, and benign strictures. This retrospective study aimed to evaluate the long-term outcomes of Roux-en-Y hepaticojejunostomy performed for various benign biliary diseases, with particular emphasis on the incidence, timing, risk factors, and management of late complications, primarily anastomotic stricture and recurrent cholangitis. MATERIALS AND
methodsThis single-center retrospective study analyzed 100 consecutive patients who underwent Roux-en-Y hepaticojejunostomy for benign biliary disease between January 2015 and March 2022. Data were retrieved from a prospectively maintained database with a minimum six-month follow-up. The median duration of follow-up was nine months (range: 6-15 months). Inclusion criteria included patients of any age with benign indications; exclusions included malignancy, major comorbidities, and referrals from other centers. Standard technique involved end-to-side anastomosis using 4-0/5-0 absorbable sutures, often via the Hepp-Couinaud approach. Statistical analysis was performed using the chi-square test.
resultsThe cohort comprised 100 patients, predominantly 66 (66%) female patients, and most commonly aged 31-40 years. The primary indication for Roux-en-Y hepaticojejunostomy was choledochal cysts in 52 (52%) patients, followed by bile duct injuries in 33 (33%) patients. Long-term complications included recurrent cholangitis in 39 (39%) patients and anastomotic stricture in 20 (20%) patients. Stricture rates were the highest among patients with bile duct injuries. There was no significant association between sex and stricture development (p = 0.58). A near-significant trend was observed between younger age (<40 years) and a higher stricture incidence (p = 0.063). Postoperative bile leakage (p = 0.021) and cholangitis (p < 0.001) were strong predictors of anastomotic stricture formation.
conclusionRoux-en-Y hepaticojejunostomy for benign biliary diseases is associated with considerable late morbidity, particularly following bile duct injury. Postoperative bile leak and early cholangitis emerged as key modifiable predictors of anastomotic stricture. From a technical perspective, construction of a wide, tension-free mucosa-to-mucosa anastomosis at the hepatic hilum, preferably using the Hepp-Couinaud approach whenever feasible, is likely protective by ensuring optimal vascularity and reducing anastomotic narrowing. Younger patients may therefore require closer surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.